A cross-sectional analysis was conducted to compare DALYs for the 15 skin conditions included in the GBD 2021 with NIH funding for these conditions in 2021‐2022. Data were sourced from the GBD Results tool [1] and the NIH RePORTER database [7]. The search parameters used in GBD Results to obtain DALY metrics for all 15 aforementioned skin disease categories in the US were as follows: measure=“DALYs,” metric=“number,” location=“United States of America,” age=“all ages,” sex=“both,” and year=“2021.” DALY metrics were specifically gathered for the United States to facilitate a direct comparison between the US-specific burden of skin diseases measured by DALYs and funding allocated by the NIH in the United States for skin disease research.

To compile a comprehensive list of NIH-funded grants awarded for skin disease research during fiscal years 2021-2022, a total of 15 queries were entered into the NIH RePORTER database, with each query corresponding to one of the GBD skin disease categories. The following parameters were used to conduct all 15 of these search queries: fiscal year=“2021 and 2022,” text search logic=“advanced,” and limit project search=“project title, project terms, and project abstracts.” In the Text Search box, all International Classification of Diseases, 10th Revision codes categorized by the GBD 2021 under one specific skin disease category were strung with “AND,” “OR,” or “NOT” as determined necessary to capture all relevant NIH-funded grants.

All titles and abstracts of the grants obtained from NIH RePORTER were manually screened by two independent reviewers to determine inclusion versus exclusion (they were included if the grant studied any 1 of the 15 skin disease categories described by the GBD 2021). Following independent review, inclusion and exclusion decisions were cross-examined to identify conflicting decisions. A third reviewer served as a tie-breaker to resolve any discrepancies as needed.

Statistical analysis was performed assuming that the proportion of DALYs attributed to a disease should be the same as the proportion of NIH skin disease funding it receives (ie, if a specific disease is responsible for 25% of all US skin disease DALYs, that disease should receive 25% of all NIH skin disease funding). A one-to-one trendline was used to visualize this relationship and identify outliers representing relatively over- and underfunded skin diseases. An “observed-to-expected” ratio was calculated by dividing the true amount of funding a disease received by the amount of funding a disease could be expected to receive assuming a one-to-one relationship between DALYs and funding.

This study was exempt from review by the institutional review board, and no patient or participant consent was required or obtained, as this study did not constitute human subjects research and used publicly available data.

This study reinvestigated the relationship between US skin disease burden and NIH skin disease research funding using the latest GBD 2021 data and NIH funding data from fiscal years 2021‐2022. Compared to Hagstrom et al’s [4] 2015 study, many of the same trends in relative over- and underfunding of skin diseases were observed. For example, malignant melanoma remains the most significantly overfunded skin disease relative to its disease burden (Table 1) [4]. Nonmelanoma skin cancer and leprosy also remain overfunded, while dermatitis, acne vulgaris, urticaria, fungal skin diseases, and cellulitis remain underfunded (Table 1) [4]. Interestingly, pruritus and decubitus ulcers, previously underfunded in 2015, now appear to be relatively overfunded (Table 1) [4]. Funding for psoriasis was well matched to its disease burden in 2015, but in our updated analysis, psoriasis is the most underfunded skin disease category. Similarly, viral skin diseases were well funded in 2015 and now appear underfunded (Table 1) [4].

It is important to consider disease burden when allocating research funding to ensure adequate resources are being directed toward diseases with the most significant impact. Dedicating more resources toward high-burden diseases can improve individual health and quality of life by driving the development of innovative treatments and can also provide long-term economic benefits by reducing health care costs and increasing overall workforce productivity.

In addition to disease burden, many other factors also significantly impact resource prioritization and funding allocation. For example, more research funding is likely to be allocated to diseases with strong public awareness and advocacy campaigns, such as malignant skin melanoma. Funding is also likely influenced by disease curability and the potential for therapeutic innovation. The NIH may also prioritize funding for diseases with lower incidence or prevalence but higher mortality (ie, metastatic melanoma, metastatic nonmelanoma skin cancer) rather than diseases with lower mortality but higher incidence or prevalence (ie, dermatitis and acne vulgaris).

It is important to keep in mind that using data strictly from the GBD study and the NIH does not fully capture all of the nuances of US skin disease burden and research funding. An important limitation of this analysis, similar to Hagstrom et al’s [4] prior study, is the exclusion of industry research funding by pharmaceutical companies and other nongovernmental entities from NIH funding data [4,7]. The NIH is the largest source of public funding for biomedical research; however, a significant portion of research funding also comes from nonprofits, philanthropic organizations, and private industry [8]. Therefore, while a disease may appear underfunded relative to its disease burden using GBD and NIH data alone, additional research funding from nongovernmental agencies may be filling this perceived gap in resource allocation. For instance, although our analysis showed that psoriasis received significantly less funding from the NIH relative to its disease burden, substantial funding from pharmaceutical companies has driven the development of innovative new drugs (ie, IL-23 and IL-17 inhibitors) that have transformed the treatment of psoriasis in recent years [9]. Similarly, previous reviews have cited US $22,291,506 in nonprofit funding for dermatology research in 2019 alone and US $9.3 billion dollars of private equity investment in dermatology health care and research between 2011 and 2021 [10,11].

Given the wide variety of factors that must be considered in order to optimally allocate research funding, several guidelines may help ensure that funding is prioritized for research efforts that will guide clinical practice, improve patient outcomes, and positively impact public health. In addition to prioritizing high-burden diseases, prioritizing funding for translational research can help expedite the incorporation of knowledge gained from basic science research into clinical practice and patient care. Periodically evaluating the real-world impact of funded research using metrics including patient outcomes and cost-efficacy can also help ensure that funding is being distributed to research that is meaningfully impacting clinical practice. Increased funding for conditions that are impacting our patients will allow innovative solutions that improve patient quality of life. With these guidelines in mind, disease burden can easily be incorporated as one of the many important factors that should be used to inform research funding allocation, clinical practice guidelines, and health policy.